We Are Crinetics

Crinetics is a pharmaceutical company that develops much-needed therapies for people with rare endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.

Watch Our Video

Read the Latest

July 29, 2021

Crinetics Pharmaceuticals Announces $15.0 Million Private Placement with Frazier Healthcare Partners

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it has entered into a securities purchase agreement with Frazier Healthcare Partners for the

June 28, 2021

Crinetics Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly

This trial will be one of two planned Phase 3 studies assessing the safety and efficacy of once-daily oral paltusotine in acromegaly patients that together will evaluate paltusotine in a wide cross section of acromegaly patients.

Pipeline

We support patients, endocrinologists, and healthcare providers by finding better therapies for rare endocrine diseases and endocrine oncology such as:

Our investigational drug for acromegaly is entering Phase 3. But that’s just at the forefront of the important work we’re doing to combat endocrine disease.
See the science >

Discovery Pre-Clinical Phase 1 Phase 2 Phase 3
Paltusotine (oral SST2 agonist)
Acromegaly
Paltusotine (oral SST2 agonist)
Neuroendocrine Tumors (NETs)
CRN04777 (oral SST5 agonist)
Congenital Hyperinsulinism (congenital HI)
CRN04894 (oral ACTH antagonist)
Cushing's Disease, Congenital Adrenal Hyperplasia (CAH)
Undisclosed Novel Program

Press Releases

crin home box pressrelease grey uai

Investor Relations

investor relations crinetics pharmaceuticals

News

crin home box news grey uai